Company Overview and News
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics Third Quarter 2017 Earnings Results Call. [Operator Instructions]. (25-0)
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics’ Second Quarter 2017 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation. [Operator Instructions] (0-1)
Stem cell therapies are a key component of the regenerative medicine field that promises to be a revolutionary approach to treating many degenerative conditions by repairing damaged tissue and harnessing the body's ability to heal itself. Biotech companies in focus include: Endonovo Therapeutics, Inc. (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), Cytori Therapeutics, Inc. (0-1)
The main biotech indices continue to push higher last week as second quarter earnings from industry stalwarts start to filter in. (0-2)
SAN DIEGO, July 24, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced top-line, preliminary data from its pivotal STAR trial of HabeoTM Cell Therapy in patients with scleroderma. While the primary endpoint, Cochin Hand Function Score (CHFS), did not reach statistical significance at 24 or 48 weeks, the trial data reported clinically meaningful improvements in the primary and secondary endpoints of both hand function and scleroderma-associated functional disability, for Habeo treated patients compared to placebo, in a subgroup of patients with diffuse cutaneous scleroderma. (0-3)
Investors in Cytori Therapeutics, Inc. (CYTX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the December 15th, 2017, $2 Call had some of the highest implied volatility of all equity options today. (0-1)
SAN DIEGO, June 08, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced the publication of long-term follow-up data reporting patient satisfaction and surveillance for cancer recurrences following use of Cytori Cell Therapy™ for breast reconstruction following partial mastectomy and radiation for breast cancer treatment. (0-1)
SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced plans to introduce its next-generation Celution® technology. The technology is available for pre-orders effective June 1st, 2017 with first product shipments anticipated to begin in Q3.
* Cytori Therapeutics Inc - now completed all 48 week follow up monitoring visits in its U.S. FDA approved phase III star trial Source text for Eikon: Further company coverage:
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.
Good afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics’ First Quarter 2017 Earnings Results Call.
MUNICH May 10 The new company formed from the planned $70 billion merger of Linde and Praxair will likely be based in Ireland with a tax domicile in Britain, its chief executive told shareholders on Wednesday.
* Cytori Therapeutics Inc - one year follow up data of adrcs (cytori cell therapy) treatment in post prostatectomy erectile dysfunction
* Vulcan Materials Co qtrly total revenues increased $33 million, or 4 percent, to $787 million
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton